Search clinical trials for: Eylea® (Aflibercept)

Total 14127 results

Singapore National Eye Centre
Santen Pharmaceutical Co., Ltd.; Singapore Eye Research Institute

Unknown

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Diabetic Macular Edema

Singapore
Vitreous -Retina- Macula Consultants of New York

Unknown

Intense Treatment Regimen With Intravitreal Aflibercept Injection (I-TRAP)

Neovascular Age-Related Macular Degeneration

United States
Unity Health Toronto

Recruiting

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept (COVARIANT)

Diabetic Macular Edema | Macular Edema | Retinal Vein Occlusion | Age Related Macular Degeneration

Canada
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
University of Alexandria

Completed

One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

Diabetic Macular Edema
Regeneron Pharmaceuticals
Bayer

Completed

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact (DA VINCI)

Diabetic Macular Edema

United States, Austria, Canada
Washington University School of Medicine
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection for Radiation Retinopathy

Macular Edema | Radiation Retinopathy

United States
Wake Forest University Health Sciences

Terminated

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Retinal Vein Occlusion

United States
Stanford University
Regeneron Pharmaceuticals

Withdrawn

A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema (DRAW-2)

Diabetic Macular Edema

United States
Advanced Eye Research Associates

Active, not recruiting

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Diabetic Macular Edema

United States
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung...

Completed

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

Center-involved Diabetic Macular Edema
Barcelona Macula Foundation
Bayer; TFS Trial Form Support

Completed

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor (MACBETH)

Wet Macular Degeneration

Spain
Maisonneuve-Rosemont Hospital
Bayer

Unknown

Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema (Eylea)

Diabetic Macular Edema

Canada
Alcon Research

Completed

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Exudative Age-Related Macular Degeneration
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Sunnybrook Health Sciences Centre

Unknown

PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept (PRaCTICAL)

Age Related Macular Degeneration | Central Serous Chorioretinopathy | Idiopathic Poplypoidal Choroidal Vasculopathy

Canada
Unity Health Toronto

Unknown

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study

Diabetic Macular Edema
Bayer

Recruiting

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Preterm Infants | Retinopathy of Prematurity

United Kingdom
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
University of California, San Diego
Regeneron Pharmaceuticals

Completed

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection (EAGLE)

Macular Degeneration | Wet Macular Degeneration

United States
Bayer

Completed

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO (CENTERA)

Central Retinal Vein Occlusion

France, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Australia
Bayer
Regeneron Pharmaceuticals

Completed

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (RETRO CRVO)

Retinal Vein Occlusion

Belgium
Wills Eye
Regeneron Pharmaceuticals

Completed

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy (CONTAIN)

Central Serous Chorioretinopathy

United States
Asan Medical Center

Unknown

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

Diabetic Retinopathy

Korea, Republic of
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Bayer

Completed

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Macular Edema

Japan
Bayer
Regeneron Pharmaceuticals

Completed

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting (INSIGHT)

Wet Macular Degeneration

Sweden
Vista Klinik
Bayer

Completed

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Neovascular Age-related Macular Degeneration
Retina Research Institute, LLC

Completed

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Choroidal Neovascularization | Presumed Ocular Histoplasmosis

United States
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Gregg T. Kokame, MD
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation (EPIC)

Polypoidal Choroidal Vasculopathy

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
Bayer
Regeneron Pharmaceuticals

Completed

Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (TITAN)

Wet Macular Degeneration

France
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland
Pusan National University Hospital
Novartis

Unknown

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) (VIBIM)

Macular Edema, Diabetic

Korea, Republic of
University of Oklahoma

Completed

Aflibercept Injection for Proliferative Diabetic Retinopathy

Vitreous Hemorrhage

United States
Bayer

Completed

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. (ANDROMEDA)

Macular Degeneration

Germany
4D Molecular Therapeutics

Recruiting

4D-150 in Patients With Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Bayer

Completed

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (BELUGA)

Neovascular Age-related Macular Degeneration

Belgium
Bayer

Completed

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America (AQUILA)

Macular Degeneration

Mexico, Argentina, Colombia, Costa Rica
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany

3

Subscribe